Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder

被引:22
作者
Albayrak, Oezguer [1 ]
Albrecht, Beate [2 ]
Scherag, Susann [1 ]
Barth, Nikolaus [1 ]
Hinney, Anke [1 ]
Hebebrand, Johannes [1 ]
机构
[1] Univ Duisburg Essen, Dept Child & Adolescent Psychiat, D-45147 Essen, Germany
[2] Univ Duisburg Essen, Univ Klinikum, Inst Humangenet, D-45147 Essen, Germany
关键词
Weight reduction; Stimulant; Dopamine; Melanocortin; Brain derived neurotrophic factor; Sympathetic nervous system; DEFICIT HYPERACTIVITY DISORDER; NEUROTROPHIC FACTOR; FUNCTIONAL-CHARACTERIZATION; INHIBITORY CONTROL; BODY-WEIGHT; DOPAMINE; OVERWEIGHT; ADOLESCENTS; CIRCUITRY; HORMONE;
D O I
10.1016/j.ejphar.2010.12.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We present the case report of a 2 year old boy with early onset extreme obesity (body mass index (BMI) 34.2 kg/m(2); body mass index standard deviation score (BMI-SDS) 5.4) who is heterozygous for a non-conservative functionally relevant melanocortin MC4 receptor mutation (Glu308Lys) and who also showed severe symptoms of attention deficit/hyperactivity disorder (ADHD). Treatment with the stimulant methylphenidate led to a sharp decrease of BMI to 21.8 kg/m(2) (BMI-SDS 2.8) within 24 months. We discuss potential mechanisms for this unusually large weight loss and suggest a potential link between the melanocortinergic and the dopaminergic systems, and the sympathetic nervous system. The potential benefit of methylphenidate in obese melanocortin MC4 receptor mutation carriers with and without co-morbid ADHD warrants further studies. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 65 条
[1]   Attention Deficit Hyperactivity Disorder in Obese Melanocortin-4-Receptor (MC4R) Deficient Subjects: A Newly Described Expression of MC4R Deficiency [J].
Agranat-Meged, Anat ;
Ghanadri, Yoad ;
Eisenber, Iris ;
Ben Neriah, Ziva ;
Kieselstein-Gross, Eva ;
Mitrani-Rosenbaum, Stella .
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2008, 147B (08) :1547-1553
[2]   Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment [J].
Altfas, Jules R. .
BMC PSYCHIATRY, 2002, 2 (1)
[3]   Molecular and behavioral interactions between central melanocortins and cocaine [J].
Alvaro, JD ;
Taylor, JR ;
Duman, RS .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (01) :391-399
[4]  
[Anonymous], 2000, American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, VFourth
[5]  
[Anonymous], CLIN GUID
[6]  
ARNSTEN AF, 2009, J PEDIAT, V154, pS43
[7]   Stimulants: Therapeutic actions in ADHD [J].
Arnsten, Amy F. T. .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (11) :2376-2383
[8]   Body weight gain induced by antipsychotic drugs: mechanisms and management [J].
Baptista, T .
ACTA PSYCHIATRICA SCANDINAVICA, 1999, 100 (01) :3-16
[9]  
BARKLEY RA, 1990, PEDIATRICS, V86, P184
[10]   Functional neuroimaging of attention-deficit/hyperactivity disorder: A review and suggested future directions [J].
Bush, G ;
Valera, EM ;
Seidman, LJ .
BIOLOGICAL PSYCHIATRY, 2005, 57 (11) :1273-1284